The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
Yoshihiko YonekawaKeisuke UeharaTakashi MizunoToshisada AibaAtsushi OguraToshiki MukaiYukihiro YokoyamaTomoki EbataYasuhiro KoderaMasato NaginoPublished in: International journal of clinical oncology (2020)
In patients with resectable CRLM, the TBS-high population had a survival benefit from NAC, while the TBS-low population benefited from AC. TBS may serve as an indicator for patients who will benefit from NAC.